Stockscreener 앱 받기
0.316
4.21%
-0.0139
시간 외 거래:
.32
0.004
+1.27%
전일 마감가:
$0.3299
열려 있는:
$0.3256
하루 거래량:
1.35M
Relative Volume:
2.35
시가총액:
$22.83M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-0.4213
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
+4.74%
1개월 성능:
+16.09%
6개월 성능:
-66.16%
1년 성능:
-63.35%
1일 변동 폭
$0.3123
$0.3336
1주일 범위
$0.2888
$0.3495
52주 변동 폭
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.316 | 22.83M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Balance Sheet Insights: Ovid Therapeutics Inc (OVID)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ovid Therapeutics Inc (OVID) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier - insights.citeline.com
Transcript : Ovid Therapeutics Inc.Special Call - marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - mx.advfn.com
Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire
Harvard Expert to Present Breakthrough Epilepsy Treatment Data at Ovid Therapeutics Event - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Sold by BNP Paribas Financial Markets - Defense World
HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World
Ovid Therapeutics Reports Q1 2025 Financial Results - TipRanks
Ovid Therapeutics (OVID): HC Wainwright & Co. Lowers Price Targe - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growt - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus
H.C. Wainwright cuts Ovid stock price target to $1.50, keeps buy rating - Investing.com
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World
What is B. Riley’s Forecast for OVID Q2 Earnings? - Defense World
Q3 EPS Estimate for Ovid Therapeutics Raised by Analyst - Defense World
Wedbush Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail
Ovid Therapeutics (OVID) Exceeds Q1 Revenue Expectations and Adv - GuruFocus
Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | - GuruFocus
Ovid Therapeutics Reports Business Updates and First Quarter 202 - GuruFocus
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc Reports Q1 2025 EPS of -$0.14, Meeting Est - GuruFocus
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results | OVID Stock News - GuruFocus
Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | OVID Stock News - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by Renaissance Technologies LLC - Defense World
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - ADVFN
Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World
Ovid Therapeutics Inc [OVID] stock for 2,956 USD was sold by ALEXANDER MARGARET A. - knoxdaily.com
The OVID Stock Puzzle: Unraveling Ovid Therapeutics Inc’s Fluctuating Performance - investchronicle.com
A closer look at Ovid Therapeutics Inc (OVID) is warranted - uspostnews.com
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ovid Therapeutics Inc 주식 (OVID) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.39%
0.42%
자본화:
|
볼륨(24시간):